糖尿病对肥厚型心肌病预后影响的GRADE荟萃分析
糖尿病与全因死亡、心力衰竭和心房颤动风险升高相关,并与左室舒张末期容积减小和整体纵向应变受损相关。证据提示应加强此类患者的心律和功能监测。
要点
- 肥厚型心肌病合并糖尿病与全因死亡、心衰和房颤风险升高相关。
- 房颤关联在50岁以下患者中更明显,在BMI≥30 kg/m²者中减弱。
- 糖尿病与左室舒张末期容积减小和整体纵向应变受损相关。
核心结论
- 糖尿病是肥厚型心肌病的重要临床风险标志,与超额死亡、心力衰竭和心房颤动相关,并伴随不良结构功能改变。
研究设计与样本
- 系统检索PubMed、Scopus、Web of Science和Cochrane至2025年1月,纳入比较成人HCM合并与不合并糖尿病的观察性研究。
主要发现
- 糖尿病与全因死亡率升高相关(OR 1.43,95%CI 1.29至1.58;高确定性)。
- 糖尿病与心力衰竭风险升高相关(OR 1.34,95%CI 1.25至1.43;中等确定性)。
- 糖尿病与心房颤动风险升高相关(OR 1.41,95%CI 1.18至1.68;高确定性)。
- 房颤关联在50岁以下患者中最明显(OR 2.55),在BMI≥30 kg/m²者中减弱。
- 糖尿病与左室舒张末期容积减小(SMD -0.26)和整体纵向应变受损(SMD 0.58)相关,异质性高、确定性低至中等。
关键数值与推荐
- 全因死亡OR 1.43(95%CI 1.29至1.58),高确定性。
- 心力衰竭OR 1.34(95%CI 1.25至1.43),中等确定性。
- 心房颤动OR 1.41(95%CI 1.18至1.68),高确定性。
- 左室舒张末期容积SMD -0.26,整体纵向应变SMD 0.58,异质性高、确定性低至中等。
- 左室射血分数、质量和室间隔厚度的证据不确定。
临床怎么用
- 对肥厚型心肌病合并糖尿病患者应加强心律监测以早期发现心房颤动。
- 对此类患者应关注心力衰竭症状并加强心功能监测。
局限性
- 纳入研究均为观察性设计,证据确定性受限于混杂和偏倚风险。
- 超声参数分析异质性高,部分结构指标证据不确定。
- 需要前瞻性研究确定靶向代谢干预能否改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus (DM) is a common comorbidity in hypertrophic cardiomyopathy (HCM) and may exacerbate arrhythmic risk, promote structural remodelling and worsen heart failure outcomes. Its overall prognostic impact and effect on cardiac structure and function in adults with HCM remain uncertain. METHOD: We systematically searched PubMed, Scopus, Web of Science and Cochrane to January 2025 for observational studies comparing adults with HCM-DM versus HCM without DM. Random-effects meta-analyses were performed to pool ORs for clinical outcomes and standardised mean differences (SMDs) for echocardiographic parameters. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework after Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) evaluation. Subgroup, sensitivity and heterogeneity analyses were undertaken. RESULT: Eight studies encompassing approximately 47 592 patients met inclusion criteria. DM was associated with higher odds of all-cause mortality (OR 1.43, 95% CI 1.29 to 1.58; high certainty), heart failure (OR 1.34, 95% CI 1.25 to 1.43; moderate certainty) and atrial fibrillation (OR 1.41, 95% CI 1.18 to 1.68; high certainty). The association with atrial fibrillation was most pronounced in patients younger than 50 years (OR 2.55) and attenuated in those with body mass index ≥30 kg/m². HCM-DM was also linked to smaller left ventricular end-diastolic volumes (SMD -0.26) and impaired global longitudinal strain (SMD 0.58), consistent with subclinical systolic dysfunction, although heterogeneity was high and certainty low to moderate. Evidence for left ventricular ejection fraction, mass and septal thickness was inconclusive. Results were robust across sensitivity analyses. CONCLUSIONS: DM is a clinically important risk marker in HCM, associated with excess mortality, heart failure and atrial fibrillation, as well as adverse structural-functional changes. These findings support closer rhythm and function monitoring in HCM-DM and highlight the need for prospective studies to determine whether targeted metabolic interventions can improve outcomes. PROSPERO REGISTRATION NUMBER: CRD420250650799.
引用
- Mirzohreh ST, Deravi N, Javanshir E, et al. Impact of diabetes on outcomes in hypertrophic cardiomyopathy: a GRADE meta-analysis. Heart. 2026. PMID: 41062258. doi:10.1136/heartjnl-2025-326085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。